Bayer Diabetes Care Launches A1CNow(R) SELFCHECK, a New A1C Monitor for A...(nt modifications during the appointment ...),Health

Date:6/2/2009

nt modifications during the appointment, rather than waiting for lab results a few days later. A1CNow SELFCHECK complements the healthcare provider-administered A1C test but is not intended to replace it or routine blood glucose testing. Bayer's A1CNow SELFCHECK, when used in conjunction with Bayer's CONTOUR(R) or BREEZE(R)2 blood glucose meters, may help patients achieve tighter control in managing their diabetes, and therefore may reduce longer term complications.

"Bayer's A1CNow SELFCHECK provides patients with a new way to partner with their healthcare providers to better achieve good blood sugar control on both a daily basis and over the long-term," said Sandra Peterson, president of Bayer Diabetes Care. "This new product builds on our history of innovation, which began with Bayer's invention of the first portable blood glucose meter 40 years ago, and represents a significant step forward in helping patients simplify life with diabetes."

A1CNow SELFCHECK, available for purchase through leading online pharmacies, comes as a 2-test-kit for a suggested sale price of $29.99. For more information or to find out where you can buy this meter, visit www.A1CNOW.com or www.A1CNOWSELFCHECK.com. These websites also contain valuable educational information for patients to help them better understand and track their A1C progress.

About A1C(1),(2)

A1C is a measure of how much sugar is attached to hemoglobin - a protein inside the red blood cells. The more sugar there is in the blood, the more will stick to hemoglobin, which increases a patient's A1C level. Once it sticks, sugar remains on the hemoglobin for the life of the red blood cell, about three months.

An A1C reading provides the average blood sugar level over the past three months and indicates how well blood s
'/>"/>

SOURCE Bayer Diabetes Care Copyright©2009 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4
Related medicine news :

1. Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
2. AUDIO from Medialink, Bayer Healthcare and Onyx Pharmaceuticals: Facts About Hepatitis
3. Bayer to Present Data on Development Compound BAY 73-4506 at 45th Annual Meeting of the American Society of Clinical Oncology
4. Now Available: Bayer Diabetes Cares CONTOUR(R) Meters in Midnight Blue and Orange Burst
5. Bayer CropScience Welcomes New Emergency Services Leader to the Institute Site
6. J&J, Schering-Plough, Novartis, Bayer vie for Top Honors at the Premier OTC / Healthcare Ad Awards
7. Bayer HealthCare Marks 20th Anniversary of World Hemophilia Day With Euro 250,000 Contribution to the World Federation of Hemophilia
8. Nick Jonas and Bayer Diabetes Care Launch Creativity Contest to Encourage Kids With Diabetes to Express Their Simple Win
9. Bayer Awards $200,000 to National Science Teachers Association to Nurture Early-Career Science Teachers
10. Bayer Consumer Care Joins Forces with WomenHeart to Fight Heart Disease
11. Podcast from Medialink, Bayer Healthcare LLC and WomenHeart: WomenHeart - Strong @Heart